3 active not recruiting, 3 recruiting, 1 withdrawn. 4 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow INCA034176: new trials by email Literature Review of INCA034176 trials Research Report on INCA034176
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Withdrawn | Mayo Clinic | 2026-06-01 | 2026-09-03 | |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-10-09 |
| Axatilimab for Sclerotic Chronic Graft-versus-Host Disease Axatilimab, Biospecimen Collection, Questionnaire Administration - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2025-08-06 | 2026-09-24 |
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD INCA034176 - Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | Active not recruiting | Incyte Corporation | 32 | 2025-06-25 | 2026-08-10 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy INCA034176, Best Available Therapy (BAT) - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Corporation | 9 | 2025-06-04 | 2026-08-25 |
| A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease INCA034176, Placebo, Corticosteroids - Chronic Graft-versus-host-disease | Phase 3 | Recruiting | Incyte Corporation | 240 | 2025-01-21 | 2026-10-30 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease INCA034176 - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Biosciences Japan GK | 21 | 2024-07-30 | 2026-10-05 |
Bronchiolitis Obliterans Syndrome (6)
Incyte Corporation (4) · Fred Hutchinson Cancer Center (1) · Incyte Biosciences Japan GK (1) · Mayo Clinic (1)
United States (4) · Germany (3) · Italy (3) · Spain (3) · United Kingdom (3) · Austria (2) · Belgium (2) · France (2) · Ireland (2) · Japan (2) · Netherlands (2) · Australia (1) · Canada (1) · China (1) · Czechia (1)
Albert Assad, MD (1) · Saurabh Chhabra, MBBS, MS (1) · Stephanie J. Lee, MD, MPH (1)
2023 (1)